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Mahanimbine, a carbazole alkaloid was isolated from an ether extract of the stem bark 
of Murraya koenigii whilst Murrayafoline A was isolated from petroleum ether extract 
of the roots of Murraya koenigii. S-Benzyldithiocarbazate is a dithiocarbazic acid Schiff 
base derived from S-alkyl esters. They were found to exhibit cytotoxic activity against 
CEM-SS human T -lymphoblastic leukemic cells. The cytotoxic activity of 
Mahanimbine, Murrayafoline A and S-Benzyldithiocarbazate that inhibit SO % growth 
(ICso) of CEM-SS were 6 Jlglml, S Jlglml and 7.S Jlglml respectively. For comparative 
purposes, the ICso of several commercial cytotoxic drugs against CEM-SS were 
determined. The inhibition effect of Mahanimbine, Murrayafoline A and S-
Benzyldithiocarbazate were better than Methotrexate (ICso > 30 Jlg/ml), Doxorubicine 
(ICso = 21 Jlglml), Cytarabine (ICso > 30 Jlglml) and Colchecine (ICso = 8 Jlg/ml). 
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These compounds were found to be less active than cis-diamine dichloroplatinwn and 
Vinorelbine tartrate with a ICso value of 3 J,lg/ml. In contrast, these three compounds 
were found to be less active against normal mouse fibroblasts cell, 3T3 with the ICso 
value of 1 1  J,lg/ml (Mahanimbine), 1 7  J,lg/ml (Murrayafoline A) and 1 0  J,lg/ml (S­
Benzyldithiocarbazate) respectively. The study showed that the proliferation of cells 
was inhibited before the cells were being killed. In addition, Mahanimbine, 
MurrayafolineA and S-Benzyldithiocarbazate caused programmed cell death by 
showing apoptotic features such as nucleus fragmentation, cell shrinkage, membrane 
blebbing and formation of apoptotic bodies. These were further confirmed with DNA 
laddering in agarose gel electrophoresis assay due to DNA fragmentation. DNA 
laddering was obtained after 24 hours of treatment by these three compounds in a dose­
independent but time-dependent way. Mahanimbine and Murrayafoline A were shown 
to arrest CEM-SS cells at G1 phase of cell cycle using flowcytometry method. As a 
result, Mahanimbine, Murrayafoline A and S-Benzyldithiocarbazate were found as 
potent antitumor agents. 
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Mahanimbine, sejenis karbazole alkaloid yang diasingkan dari ekstrak eter daripada 
batang kulit kayu Murraya koenigii manakala Murrayafoline A diasingkan dari ekstrak 
petrolium eter daripada akar Murraya koenig;i. S-Benzyldithiocarbazate pula adalah 
asid dithiocarbazik Schiff bas yang dihasil daripada ester S-alkyl. Mereka didapati 
menunjukkan akitiviti sitotoksik ke atas jujukan sel T -lymphoblastik leukemik manusia, 
CEM-SS. Aktiviti sitotoksik Mahanimbine, Murrayafoline A dan S-
Benzyldithiocarbazate yang dapat merencatkan pertumbuhan sel CEM-SS sebanyak 50 
peratus (ICso) adalah 6 �g/ml, 5 �g/ml and 7.5 �g/ml masing-masing. Untuk tujuan 
perbandingan, ICso bagi beberapa jenis dadah sitotoksik komersial ke atas CEM-SS juga 
ditentukan. Kesan perencatan Mahanimbine, Murrayafoline A and S-
Benzyldithiocarbazate adalah lebih baik daripada Methotrexate (ICso > 30 �g/ml), 
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Doxorubicine (ICso = 21 J.1g/ml), Cytarabine (ICso > 30 J.1g/ml) dan Colchicine (ICso = 8 
J.1g/ml). Sebatian-sebatian ini adalah kurang aktif berbanding dengan cis-diamine 
dichloroplatinum dan Vinorelbine tartrate dengan nilai ICso 8 J.1g/ml. Sebaliknya, 
ketiga-tiga sebatian ini didapati kurang aktif ke atas jujukan sel fibroblast tikus yang 
normal, 3T3 dengan nilai ICso 11 J.1g/ml (Mahanimbine), 17 J.1g/ml (Murrayafoline A) 
dan 10 j.lg/ml (S-Benzyldithiocarbazate) masing-masing. Kajian ini telah menunjukkan 
bahawa pertumbuhan sel-sel akan direncatkan sebelum mereka terbunuh. Tambahan 
lagi, Mahanimbine, Murrayafoline A dan S-Benzyldithiocarbazate mengarahkan 
kematian sel terprogram dengan menunjukkan sifat apoptotik seperti penyerpihan 
nukleus, pengecutan sel, membran membengkak dan pembentukkan badan apoptotik. 
Penentuan secara lebih lanjut telah ditunjukkan dengan pembentukkan "tangga DNA" 
dalam elektrophoresis gel agarose terhasil dari penyerpihan DNA. Tangga DNA 
didapati selepas rawatan 24 jam oleh ketiga-tiga sebatian secara bergantung kepada 
masa rawatan dan bukan dos. Mahanimbine and Murrayafoline A dapat menahan CEM­
SS sel pada fasa G1 dengan menggunakan flowsitometri. Justeru itu, Mahanimbine, 
Murrayafoline A dan S-Benzyldithiocarbazate didapati berpotensi sebagai agen 
antibarah. 
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CHAPTER ! 
INTRODUCTION 
Cancer is now the public's most feared disease. The global incidence of cancer 
is soaring due to rapidly aging populations in most countries. Over the next 25 years 
there will be a dramatic increase in the number of people developing cancer. Globally, 
10 million new cancer patients are diagnosed each year and this will surge to 20 million 
by the year 2020 (Sikora, 1999). American Cancer Society reported that since 1990, 
approximately 12 million new cancer cases have been diagnosed. In the states, about 
1,268,100 Americans are expected to die of cancer in the year of 2001- more than 3000 
people a day. This increment is fuelled in part by the globalization of unhealthy 
lifestyles. Billions of dollars are spent annually, on cancer research by the drug industry, 
but a cure for cancer appears illusive. 
Comprehensive articles on areas as wide-ranging as chemoprevention, cancer 
genetics and human cancer therapy have stimulated great interest. An understanding of 
the varied mechanisms leading to cancer has favored the development of many new 
cancer therapies, most notably perhaps the emergence of curative cytotoxic drug 
treatments of some previously uniformly fatal forms of cancers. Dramatic technological 
change is likely in surgery, radiotherapy and chemotherapy to increase cure rates, but at 
a pnce. 
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Decades of modern treatments have taught us that cancer is a "smart" disease 
and surgery has become conservative due to technological improvements. Therefore, 
the role of chemotherapy has become more defined to beat "smart" cancer cells via 
smarter therapies. This is a considerable challenge. It is matched, however by the real 
sense of excitement that has developed in the field of new anticancer drug discovery 
(Baring, 1997). This excitement is based on the premise that we can design much 
smarter and more effective therapies by aiming to counteract or exploit the very genetic 
and biochemical abnormalities that drive the disease itself (Workman, 1994). The 
treatments of the next century will be rationally designed, less toxic and more effective. 
The third millenium is upon us and achievements in cancer research had reached 
to a stage where tremendous technological advances for cancer are available to millions 
of patients suffering from and succumbing to unconquered neoplastic diseases. Besides 
that, there is enormous potential for the discovery of innovative cancer drugs with 
imporved efficacy and selectivity for this millenium. The world is in a health transition 
and cancer drug discovery is re-inventing itself, in order to exploit the latest intellectual 
technological developments. Hopefully in the next 25 years, will be a time of 
unprecedented change in the way in which we will control cancer. 
There are four major phases in drug discovery, target identification and 
validation, lead identification, lead optimization and clinical drug candidate and in this 
study, the very early stage of drug discovery was being emphasized. Two natural 
products Mahanimbine, Murrayafoline A isolated from Murraya koenigii (curry leaf) 
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whose leaves are widely used in local cooking and a synthetic compound S­
Benzyldithiocarbazate were being approached and studied in order to discover their 
enormous potential as chemotherapeutic drugs on T -lymphoblastic leukemia. 
The objectives of this study are: 
i) to determine the cytotoxicity of Mahanimbine, Murrayafoline A and S­
Benzyldithiocarbazate on human T -lymphoblastic leukemic, CEM-SS cell. 
ii) To study the effect of Mahanimbine, Murrayafoline A and S­
Benzyldithiocarbazate on CEM-SS cells in terms of proliferation, morphological 
changes and the mode of cell death induced by the compounds. 
iii) To identify the mode of action of Mahanimbine, Murrayafoline A and S­
Benzyldithiocarbazate. 
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2.1 Traditional Medicine 
CHAPTER 2 
LITERATURE REVIEW 
Traditional medicine using herbal exists in every part of the world. In the history of 
medicine, the necessity of helping sick people goes back to the origin of mankind. In many 
places of the world special ways of medical treatment were found. By looking back into 
history, we found that nearly all cultures from ancient times until the present day have been 
using plants as a source for medicine. Generally, we can distinguish three major areas of 
traditional medicine: Chinese, Indian and European and the art of practicing herbal 
medicine stretches back over more than thousand of years (Vogel, 1991). However, there 
are a few basic difficulties that traditional medicine not accepted worldwide. The Health 
Authorities of this individual country mostly accept the experiences gathered in one cultural 
area but not by another Health Authority elsewhere. Another basic difficulty is the fact that 
traditional medicine usually consists of many herbal or animal or inorganic ingredients. 
There is a wide variation in the quantity of pharmacological active substances in each plant. 
Differences in methods of extraction and purification influence the results. Besides that, it 
is quite often traditional recipes lacked of sufficient quality control and drug 
standardization. (Vogel, 1991). Therefore, it's important to internationalize some 
standardize extracts from these herbal drugs by going through a required developing 
procedures from Health Authority. 
4 
2.2 Family Rutaceae 
This family comprises trees, shrubs and climbers recognized from their resinous, 
lime-like smell of the broken twigs, fruits or of the crushed leaves. Many essential oils such 
as citronella and bergamot are extracted by distillation from plants of this family and mostly 
of these oils are used in native medicine (Kirthika and Basu, 1935). 
This family consists of 161 genera and 1700 species throughout the world and found 
mostly in warm countries (Mabberly, 1987). In Malaysia, there are 16 genera and 50 
species and mostly are found in lowland area. 
2.2.1 Genus Murraya 
Genus Murraya is from Angiosperma's division, Dycotilidon's Class, Sepindales's 
order, Rutaceae's (Lemon) family (Heywood, 1979) and Aurantiodea's subfamili. Genus 
Murraya was named after John Andrew Murray (1740-1791), a Sweedish botanist. Among 
the seven species from this genus, only Murraya panicu/ata has aromatic flowers (Huxley, 
1992). Murraya koenigii (curry leaf) is one of the most widely used plants whose leaves are 
added to curries to improves flavor. It is usually cultivated for its aromatic smell, which are 
used as natural flavorings in curries and sources (Sastri, 1952). 
Various parts of M koenigii have many medicinal uses and values as raw material 
for traditional medicine and popular in �dia (Kirthikar and basu, 1935). It have been 
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reported that the leaves and the roots can cure piles and heat removal of the body, 
inflammation and itching, while the powdered leaf is used to aid healing of fresh cuts. The 
green leaves could be eaten raw for the treatment of dysentery (Drury, 1978). Barks and 
roots are used to relieve skin eruptions and bites by poisonous animals (Dasturs, 1970). 
Currently, this plant has been used in the industry, where fresh leaves are steam distilled 
under reduced pressure to yield volatile oils (curry leaf oil) which can be used as a fixative 
for a heavy type of soap perfume (Joseph e t  al.,1985). Biological activities of Malaysia 
plants were first reported by Nakashini e t  al. in 1965. Murraya koenigii has been proven to 
be a rich source of carbazole alkaloids. Isolation work on the stem bark carried out by Reish 
e t  al. 1994 gave a new non-cyclized compound that postulated as biogenetic precursors of 
mahanimbine. 
2.2.2 Murraya koenigii and its uses 
Murraya koenigii is a member of the large Rutaceae family and represented by 
about 161 genera and 1700 species. In Malaysia, nearly 60 species of this family can be 
found including two species of Murraya: namely M. koenigii and M. panicluata. 
M. koenigii (curry leaf) is one of the most widely used plants whose leaves are 
added to curries to imporves flavour. This intensive pungent, aromatic leaves are best when 
fresh, but adequately retain their potency for some time after picking. 
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2.3 Cancer 
Cancer is a genetic disease, because it can be traced to alterations within specific 
genes, but in most cases, it is not an inherited disease. The genetic alterations that lead to 
most cancers arise in the DNA of a somatic cell during the lifetime of the affected 
individual. Because of these genetic changes, cancer cells proliferate uncontrollably, 
producing malignant tumors that invade surrounding healthy tissue (Karp, 1999). 
Because of its impact on human health and the hope that a cure might be developed, 
cancer has been the focus of a massive research effort for decades. Cancer researchers have 
been working for many years to develop more effective and less debilitating treatments. 
Current treatments, such as chemotherapy and radiation, lack the specificity needed to kill 
cancer cells without simultaneously damaging normal cell, as evidenced by the serious side 
effects that accompany these treatments (Karp, 1999). 
2.3.1 The Biology of Cancer 
At the cellular level, the most important characteristic of a cancer cell is its loss of 
growth control. When malignant cells or so-called neoplasm in the scientific or medical 
term are cultured on a culture dish under a limited growth factor condition, they continue to 
grow, pilling on top of one another to form clumps (Albert, 1989). Malignant cells escape 
from many of the normal homeostatic mechanisms that control proliferation (Goodman 
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1994). Transformation of normal cells to neoplasm cells may be triggered by several 
factors, including chemical exposure, viruses and radiation. This showed that malignant 
cells are not responsive to the types of regulatory signals that cause their normal 
counterparts to cease growth and division. Uncontrolled growth combined with the 
tendency to become metastatic makes malignant cells the deadly threat that they are. 
2.3.2 Classification of Tumors 
Generally there are two kinds of tumors benign and malignant. Benign tumor is a 
tumor composed of cells that are no longer responsive to normal growth controls, but that 
lack the capability to invade normal tissues or metastasize to distant sites whereas 
malignant tumors often spread to neighboring tissues and even other parts of the body 
(Albert, 1989). 
2.3.3 The Genetics of Cancer 
Whenever cells of cancerous tumor are genetically scrutinized, they are invariable 
found to have arisen from a single cell. Cancer results from the uncontrolled proliferation of 
a single wayward cell (cancer is said to be monoclonal). Malignant transformation requires 
more than a single genetic alteration. The development of a malignant tumor is a multistep 
process characterized by a progression of genetic alterations in a single line of cells that 
makes the cells increasingly less responsive to the body's normal regulatory machinery and 
able to invade normal tissues (Karp, 1999). 
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